PHASE II MULTIPLE-DOSE TREATMENT OF TYPE 1 DIABETES MELLITUS

1 型糖尿病的 II 期多剂量治疗

• 批准号: 7603484
• 负责人: William A. Hagopian
• 金额: $ 0.23万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603484
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Control Groups; Diagnosis; Dose; Funding; Grant; Immune; Institution; Insulin; Insulin-Dependent Diabetes Mellitus; Label; Morbidity - disease rate; Participant; Patients; Pharmaceutical Preparations; Phase; Phase II Clinical Trials; Production; Protocols documentation; Publishing; Randomized; Research; Research Personnel; Resources; Safety; Site; Source; Structure of beta Cell of islet; United States National Institutes of Health; Universities; Upper arm; alanylalanine; base; clinical efficacy; glycemic control; improved

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-centered, 2 arm, randomized, open label, Phase II trial involving 0 or 2 cycles of treatment one year apart using the immune suppressive drug hOKT3yl (Ala-Ala) in patients with new onset type 1 Diabetes Mellitus (T1DM). It is hypothesized that hOKT3 will arrest the loss of insulin production of the pancreatic beta cells during the first 2 years from diagnosis and improve glycemic control. Greater glycemic control has been shown to result in less long-term TIDM morbidity. Participants will be randomized to drug treatment (Group A) or control (Group B). There is dose escalation within each cycle, but no change between cycles. The randomization will be 2 drug subjects to 1 control subject and will be stratified by study site. The current protocol is based on Phase I/II and PK/Safety trials conducted at Columbia University that suggested clinical efficacy as published in the NEJM in May 2002, and demonstrated safety of the drug.

这个子项目是众多研究子项目之一